Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
February 20, 2019 Off

ADC Therapeutics doses patients in testing ADCT-402, after encouraging safety profile and anti-tumor activity

By Dino Mustafić

Oncology drug specialist ADC Therapeutics has continued with its Phase I clinical trial of combination of ADCT-402 (loncastuximab tesirine) with Pharmacyclics LLC’s ibrutinib, by dosing patients with advanced diffuse large B-cell lymphoma (DLBCL) or mantle cell lymphoma (MCL).

Beximco buys eight ANDAs in US from Novartis’ Sandoz
February 20, 2019 Off

Beximco buys eight ANDAs in US from Novartis’ Sandoz

By Dino Mustafić

Beximco Pharmaceuticals Limited will buy from Novartis’ Sandoz a portfolio of eight Abbreviated New Drug Applications (ANDAs) in the US…

February 19, 2019 Off

Pfizer Lilly use tanezumab to treat moderate-to-severe chronic low back pain in phase 3 study, it works

By Dino Mustafić

Pfizer and Eli Lilly have been testing tanezumab in patients with moderate-to-severe chronic low back pain (CLBP) in a Phase 3 study, with certain success, as tanezumab 10 mg met the primary endpoint by reducing pain at 16 weeks compared to placebo.

Roche to get quicker review of its anti cancer Rituxan combination, in August
February 19, 2019 Off

Roche to get quicker review of its anti cancer Rituxan combination, in August

By Dino Mustafić

Roche on Tuesday got nod from the US Food and Drug Administration (FDA) that it’s anti-cancer combination might have the potential to provide significant improvements in the safety and effectiveness of the treatment, prevention or diagnosis of a serious disease.

Basilea’s revenue grew year over year boosted by Cresemba and Zevtera
February 19, 2019 Off

Basilea’s revenue grew year over year boosted by Cresemba and Zevtera

By Dino Mustafić

Basilea Pharmaceutica’s revenue grew of 31% for the full year, reaching CHF 133 million (€117M), the company said on Tuesday, noting it’s year-end cash position being at CHF 223 million.

February 15, 2019 Off

Spring Pharmaceutical Group 13% revenue growth, third quarter net profit $4.5M

By Dino Mustafić

Jining, Shandong Province-based Spring Pharmaceutical Group, Inc. posted net income of $4.34 million, compared to $2.78 million for the same period of the prior fiscal year.

February 14, 2019 Off

California court allows HIV drug personal injury cases against Gilead

By Dino Mustafić

The Superior Court of California, County of Los Angeles rejected all but one of Gilead’s arguments to dismiss the HIV/AIDS patients’ legal theories against the company’s TDF-based HIV/AIDS drug, that cause permanent damage tokidneys and bones.

February 12, 2019 Off

Boehringer, IBM to test blockchain technology can help in clinical trials

By Dino Mustafić

Canadian Boehringer Ingelheim and IBM Canada want to find out how blockchain technology can help in clinical trials, the Boehringer…

February 12, 2019 Off

ReGenTree, Ora in mutual clinical study drug to treat dry eye syndrome

By Dino Mustafić

ReGenTree and Ora will mutually start testing the ReGenTree’s new drug RGN-259 for the treatment of dry eye syndrome, in a clinical study named ARISE-3, based entirely on the results of a previous clinical trials, ARISE-1 and ARISE-2.

Recipharm names new USA and Canada business manager
February 12, 2019 Off

Recipharm names new USA and Canada business manager

By Dino Mustafić

Recipharm, the contract development and manufacturing organisation (CDMO), has appointed a new director of business management for the USA and Canada, the company said in a press release on Tuesday.

Posts pagination

Previous 1 … 3,364 3,365 3,366 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine